The firm said in a statement that by agreeing to resolve claims with the HM Revenue & Customs dating between 1996 and 2010, it was able to upgrade its earnings outlook for 2010.
“AstraZeneca has increased its 2010 target for core earnings per share from $5.75-6.15 to $5.90-6.30 per share,” the statement said.
AstraZeneca stock rose by one percent on the London Stock Exchange after announcement.
Member comments